Congratulations to our partner, Claritas Genomics, for securing $15 million in capital for its Series B round to expand its commercial operations, launch new next generation sequencing-based tests for diagnosis of pediatric genetic disorders and continue to build its network of clinical pediatric disease experts.

WuXi NextCODE Genomics led the investment, joining A round investors Boston Children’s Hospital, Cerner Corporation and Cincinnati Children’s Hospital Medical Center, who participated in the B round.  Claritas will use WuXi NextCODE Genomics’ software platform to speed the performance and delivery of genetic test results and to provide a seamless interface for both the research and clinical community.

Claritas Genomics is a clinical genetic diagnostic testing laboratory spun out of Boston Children’s Hospital.  With 40% of pediatric disorders understood to have a clear genetic basis today, Claritas is positioned to combine the clinical expertise of the world’s best pediatric specialists with next generation sequencing technology to set new standards of precision for understanding the genetics of pediatric conditions and improving physicians’ ability to accurately diagnose and manage these disorders.  WuXi NextCODE is proud to contribute to Claritas’ effort with our technology and as part of a group of industry-leading stakeholders.


Related Links:

WuXi Acquires NextCODE Health to Create Global Leader in Genomic Medicine
WuXi Provides Enhanced Genomics Services for Chinese Researchers